Eli Lilly posts new positive Phase 3 obesity drug data for oral GLP-1 Foundayo and retatrutide

 

• Post-hoc Phase 3 ATTAIN-1 and ATTAIN-2 analyses show Foundayo weight loss benefits across all stages of menopause.
• Post-hoc analyses show Foundayo delivers significant weight loss even in women with type 2 diabetes.
• Additional Phase 3 retatrutide results from TRIUMPH-1 and TRANSCEND-T2D-1 demonstrate large, sustained weight loss outcomes.

https://finviz.com/stock?t=LLY&p=d